Codexis Stock (NASDAQ:CDXS)
Previous Close
$5.28
52W Range
$2.53 - $6.08
50D Avg
$4.19
200D Avg
$3.43
Market Cap
$401.19M
Avg Vol (3M)
$666.01K
Beta
2.07
Div Yield
-
CDXS Company Profile
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Performance
Revenue Breakdown
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. |
| IPSC | Century Therapeutics, Inc. |
| GBIO | Generation Bio Co. |
| NRIX | Nurix Therapeutics, Inc. |
| NUVB | Nuvation Bio Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| STTK | Shattuck Labs, Inc. |
| NKTX | Nkarta, Inc. |